The total number of records retrieved from this search are 25. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1449	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentrationLog10 pfu/cell	In-vitro result20% cell survived 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1455	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.577 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1461	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 0.303	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1467	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.159	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1473	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.329 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1479	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 0.061	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1485	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (0.08 +/- 0.04 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.011	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1491	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.579	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1497	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.487	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1503	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.530	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1509	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.546	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1515	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.207	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1521	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (3.51+/- 1.15, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.342	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1527	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.630	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1533	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75 % cell death at CI 0.249	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1539	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.285	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1545	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.207	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1551	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.092	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1557	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (0.02+/- 0.01, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.369	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1563	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:2)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.316	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1569	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:2)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.056	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1575	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:2)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.019	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1581	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.367	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1587	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.052	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1593	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(1.49+/-1.09nm, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineNCI-H23	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.008	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950